BioSpace News Archive

Top Wall Street biotech analysts are finding themselves in high demand, with staggering pay packages to go along with it, The Wall Street Journal reports.

Touting that it is helping fight the opioid epidemic, Emergent BioSolutions is acquiring Adapt Pharma. Under the terms of the deal, Emergent will pay $635 million up front and up to $100 million in cash for various sales-based milestones through 2022.

As President Donald Trump attempts to revise the North American Free Trade Agreement (NAFTA) between the U.S., Mexico and Canada, generic drugmakers have expressed concern over some of the negotiating points.

Gilead Sciences announced the appointment of Laura Hamill as executive vice president, Worldwide Commercial Operations, and member of the company’s senior leadership team.

Recently, Milton Packer, a renowned cardiologist at Baylor Scott & White Health, wrote a criticism of the Orphan Drug Act and the resulting problems caused by the biopharma industry. John LaMattina, formerly president of Pfizer Global Research and Development and a current senior partner at PureTech Ventures, responded to the editorial in Forbes. Let’s take a look.

Bristol-Myers Squibb has appointed Christopher Boerner to replace Murdo Gordon, who left the company on August 3. Boerner will take on the positions of executive vice president and chief commercial officer, effective immediately.

The U.S. Food and Drug Administration (FDA) warned four online networks that operate 21 websites selling opioids online. The warning indicates they were “illegally marketing potentially dangerous, unapproved, and misbranded versions of opioid medications, including tramadol.

Whether you’re a recent graduate about to embark on your career or a seasoned professional navigating the difficult waters of professional development and career pathing, a mentor can be an invaluable resource for career advice, support, connections, and encouragement.

Antibe Therapeutics Inc. filed its financial and operating results on Wednesday, August 29th for the fiscal quarter ended June 30, 2018.

STERO Biotechs Ltd., has received a notice of allowance and will be granted an official U.S. patent on October 2018, covering over 100 Autoimmune & chronic inflammatory diseases.